⌘K
t
ProBiotix Health plc (AQSE: PBX) announced on 3 November 2025 that it has met the eligibility criteria to join the Apex segment of the Aquis Stock Exchange Growth Market. The company's ordinary shares will be admitted to trading on this segment with effect from Monday, 10 November 2025.
| Date | 3 Nov 2025 |
| Time | 07:00:12 |
| Category | Miscellaneous |
| ID | 7926F |
3 November 2025
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Admission to trading on the Apex Segment of the Aquis Stock Exchange Growth Market
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that it has met the eligibility criteria to join the Apex segment of the Aquis Stock Exchange Growth Market and that the ordinary shares in the Company will be admitted to trading on that segment with effect from Monday, 10 November 2025.
The Apex segment caters for larger, more established businesses, and applies additional eligibility criteria, including higher governance standards, to encourage greater transparency and liquidity.
Steen Andersen, Chief Executive of ProBiotix, said:
"We are delighted to be joining the Apex segment of the Aquis Stock Exchange Growth Market. ProBiotix and its Directors have always focused on strong governance and the principles set out in the QCA Code, and we believe that today's transition is a timely validation of our company's maturity and commercial achievements. We look forward to working with Aquis and our shareholders to derive the maximum benefit from the Apex listing."
David Stevens, Chief Executive of Aquis Exchange, said:
"We're pleased to see ProBiotix take this next step on the Aquis Stock Exchange Growth Market. Their move to the Apex segment reflects their continued progress and ambition, and we're proud that Aquis provides an environment designed to support companies as they scale and broaden their investor reach."
The Directors of the Company are responsible for the contents of this announcement.
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
AlbR Capital Limited
Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
|
|
|
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a singular approach: discovering groundbreaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.